<DOC>
	<DOCNO>NCT02251977</DOCNO>
	<brief_summary>The primary objective study assess efficacy monosialotetrahexosylganglioside ( GM1 ) prevent oxaliplatin induced neurotoxicity colorectal cancer patient receive oxaliplatin-based adjuvant chemotherapy .</brief_summary>
	<brief_title>Effect GM1 Prevention Oxaliplatin Induced Neurotoxicity Stage II/III Colorectal Cancer</brief_title>
	<detailed_description>Oxaliplatin key agent treatment colorectal cancer . However , peripheral neuropathy markedly limit use oxaliplatin . Many drug try decrease development oxaliplatin induce peripheral neurotoxicity , however , result remain disappointing . This multi-center , randomize , placebo-controlled trial perform assess efficacy monosialotetrahexosylganglioside ( GM1 ) prevent oxaliplatin induced neurotoxicity colorectal cancer patient receive oxaliplatin-based adjuvant chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Age : 1875 year old , male female Histologically confirm diagnosis colorectal adenocarcinoma phase II III disease , within 2 month radical resection , intend receive 6 month adjuvant chemotherapy mFOLOFX6 XELOX , without adjuvant radiation indication No prior level peripheral nerve system disease Patients receive possible neurotoxicreactioncausing drug ( oxaliplatin , cisplatin paclitaxel drug etc ) With capability accurately record occurrence severity neurotoxicity questionnaire With normal function major organ No contraindication chemotherapy Life expectancy â‰¥ 3 month Patients provide sign Informed Consent Form Patients receive radical resection , expect able complete 6 month adjuvant chemotherapy Patients receive palliative chemotherapy Patients need adjuvant palliative radiotherapy chemotherapy Be allergic GM1 Hereditary abnormal metabolism glucose lipid Doctors believe patient suitable receive GM1 treatment With confirmed history neurological psychiatric disorder , include epilepsy dementia With concomitant disease seriously harm patient ' safety impact completion study Patients ( male female ) fertility possibility willing take effective contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>